Virios Therapeutics (Virios Therapeutics) Price-to-Tangible-Book : 1.58 (As of Jun. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Price-to-Tangible-Book?

As of today (2024-06-01), Virios Therapeutics's share price is $0.2183. Virios Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.14. Hence, Virios Therapeutics's Price to Tangible Book Ratio of today is 1.58.

The historical rank and industry rank for Virios Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

VIRI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59 Med: 2.62 Max: 5.48
Current: 1.56

During the past 6 years, Virios Therapeutics's highest Price to Tangible Book Ratio was 5.48. The lowest was 0.59. And the median was 2.62.

VIRI's Price-to-Tangible-Book is ranked better than
74.08% of 1219 companies
in the Biotechnology industry
Industry Median: 2.77 vs VIRI: 1.56

A closely related ratio is called PB Ratio. As of today, Virios Therapeutics's share price is $0.2183. Virios Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.14. Hence, Virios Therapeutics's P/B Ratio of today is 1.58.

Virios Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Virios Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Price-to-Tangible-Book Chart

Virios Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

2.08

2.94

0.59

2.90

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.13	5.48	3.74	2.90	3.47

Competitive Comparison of Virios Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Virios Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virios Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's Price-to-Tangible-Book falls into.

Virios Therapeutics Price-to-Tangible-Book Calculation

Virios Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	0.2183	/	0.138
	=	1.58

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Virios Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009